Avanos Medical: MACD Death Cross and KDJ Death Cross Triggered on 15min Chart

Avanos Medical's 15-minute chart has triggered a MACD Death Cross and a KDJ Death Cross at 08/11/2025 10:00, suggesting that the stock price has the potential to continue declining. The momentum of the stock price is shifting towards the downside and may further decrease.

Avanos Medical, Inc. (AVNS) has experienced a significant technical setback with the appearance of a MACD Death Cross and a KDJ Death Cross on its 15-minute chart as of August 11, 2025, at 10:00. These indicators suggest that the stock price is poised to continue its downward trajectory, with momentum shifting towards a negative direction and potentially leading to further declines.

The company reported mixed financial results for the second quarter of 2025, with adjusted earnings per share (EPS) from continuing operations declining 50% year over year to 17 cents, missing the Zacks Consensus Estimate by 5.6% [1]. Gross revenue for the quarter was $175 million, up 1.9% year over year, and exceeded the Zacks Consensus Estimate by 4.7%. Despite strong performance in the Specialty Nutrition Systems (SNS) portfolio and radiofrequency ablation (RFA) generator sales, the Pain Management and Recovery (PM&R) segment faced challenges, with revenues declining by 2.9% year over year.

The company's cash position remained relatively stable, with cash and cash equivalents at $90.3 million at the end of the second quarter, compared to $97 million at the first-quarter end. Total debt decreased slightly to $105.1 million from $107.4 million. However, Avanos Medical continues to face a volatile tariff environment, with estimated incremental manufacturing costs of approximately $15 million for the year [1].

The MACD and KDJ Death Cross signals a potential continuation of the downward trend in Avanos Medical's stock price, driven by the company's ongoing challenges in specific segments and the broader impact of tariffs. Investors should closely monitor the company's financial performance and strategic initiatives to mitigate these challenges.

References:
[1] https://www.nasdaq.com/articles/avanos-medical-stock-down-q2-earnings-miss-estimates-margins-down
[2] https://www.marketbeat.com/stocks/NYSE/AVNS/